Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODIFY: Modafinil in Cancer-Related Fatigue
NCT05333250Phase 2Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) comparing Modafinil with Placebo (2 arms). Primary endpoints: Fatigue at 2 weeks, Recruitment rate at 2 years and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
modafinil
03
Conditions
cancer-related fatigue (CRF)cancer-related cognitive impairment (CRCI)
Beyond the preview
Go deeper on NCT05333250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333250.